UK & Europe AA Gill takes swipe at NICE in final column NHS initially denied late writer immunotherapy.
News Opdivo gains European approval for Hodgkin lymphoma Latest approval for Opdivo good news, but won't make up for lung cancer setback
Views & Analysis NICE and NHS England unveil ‘fast-track’ and affordability s... NHS England will be able to control cost impact of NICE decisions more directly.
ESMO2016 Cancer Market Commentary: Keytruda’s triumph not the last wo... Despite Keytruda's overwhelming victory, it's not over yet in NSCLC
ESMO2016 Cancer market commentary: Roche’s Tecentriq muscles into NSC... Roche's PD-L1 drug has generated impressive data in second line lung cancer
News BMS and Nektar to pair Opdivo with natural killer cell drug BMS and Nektar's combination latest in frenzied immunotherapy field
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
